Pfizer's "external partner management" process is not exactly "American Idol" and Pfizer's John F. Kelly is not exactly Simon Cowell, but this year the Pfizer Global Supply (PGS) unit will go through the exercise of turning a handful or two of its more than 200 contractors into stars.
By Eric Palmer
Ganesh Kaundinya, chief scientific officer at biologics and biosimilars developer Momenta Pharmaceuticals, doesn't mind a little regulatory uncertainty. For those responsible for mapping a manufacturing strategy for biosimilars, these uncertainties add to the pressure of an already complex and challenging endeavor. Read the report >>
Brought to you by CMC Biologics
Being the largest company by any number of measures--revenues, earnings, those kinds of yardsticks--is a good thing. Being the largest by number of employees is trickier, unless yours is also the largest by those other measures. As we have seen time and again in recent years in the pharma industry, having lots of employees and falling revenues is a formula that leads to layoffs. As a whole, the top 10 companies had fewer employees at the end of 2012 than at the end of 2011. Read the full report >>
POPULAR COMMENT THREADS
Ranbaxy Laboratories wants the world to know it is not the same company it was when it lied to the FDA and tried to hide serious manufacturing and drug quality problems that led to last week's felony convictions for the Indian drugmaker. Today it laid out many of the of the improvements it has made since the fraud, like adding independent members to its board of directors.
Another of India's large generic drugmakers has found itself in serious problems with the FDA. Just a week after Ranbaxy Laboratories' $500 million settlement, Wockhardt says the FDA has issued an import alert that could cost it $100 million in lost sales.
GlaxoSmithKline is pretty proud of its rotacaps and its blow-fill-seal lines at its packaging plant in the Melbourne, Australia, suburb of Boronia. Its tablet line, not so much, and the drugmaker will eliminate that line and lay off about a third of the workforce at the facility.
Just months after signing a consent decree for the manufacturing mess in its Ben Venue subsidiary, Boehringer Ingelheim finds itself on the firing line with the FDA again, this time for particle contamination in an API produced 4 and 5 years ago.
Saudi Arabia is drawing yet more interest from companies that see potential from manufacturing drugs there. The Indonesian company Pharmaniaga is teaming with Saudi Arabia-based Modern Healthcare Solutions to build a drug manufacturing plant.
Johnson & Johnson just can't seem to get its consumer health manufacturing in order.
From Our Sister Sites
France's Stentys is celebrating more positive clinical data stemming from the use of its self-apposing stent to treat acute heart attacks.
An FDA import ban can be costly, and India's Wockhardt says the import alert it is now under could slice $100 million out of its revenues.